Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111)
. No severe vaso-occlusive events (VOEs) were reported through 24 months of follow up in Group C patients of the HGB-206…
. No severe vaso-occlusive events (VOEs) were reported through 24 months of follow up in Group C patients of the HGB-206…
Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations T ime Course…
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer…
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Bre…
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZe…
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-clas…
Market Scenario: Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called…
Daily dosage of oral, anti-mitotic Eg5 inhibitor shows good safety and tolerability. Specifically, no peripheral neuropa…
. - 4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucia…
The total global market for specialty injectables currently sits at $85 billion and will exceed $110 billion in 2020, ac…